OR WAIT null SECS
© 2021 MJH Life Sciences and Urology Times. All rights reserved.
© 2021 MJH Life Sciences™ and Urology Times. All rights reserved.
August 10, 2021
The application for adjuvant pembrolizumab in renal cell carcinoma is supported by data from the phase 3 KEYNOTE-564 trial, which were presented at the 2021 ASCO Annual Meeting.
July 30, 2021
The combination achieved a high objective response rate among patients previously treated with immune checkpoint inhibitors.
July 21, 2021
“To our knowledge, this study represents the first attempt to assess the associations between demographic factors and receipt of non–guideline-based treatment among patients with kidney cancer,” the authors of the study wrote.
July 19, 2021
Bradley McGregor, MD, explains how despite the groundbreaking immunotherapy-based advances in metastatic renal cell carcinoma, unmet medical needs remain.
July 14, 2021
Adjuvant pembrolizumab reduced the risk of disease recurrence or death versus placebo in the phase 3 KEYNOTE-564 trial, but overall survival data are still immature.
July 02, 2021
Neoadjuvant stereotactic ablative radiation followed by radical nephrectomy and thrombectomy was safe and showed signs of positive clinical activity in patients with renal cell carcinoma and inferior vena cava tumor thrombus.
June 01, 2021
The guideline was initially published in 2013 and was last amended in 2017.
May 21, 2021
"Certainly, telemedicine is not a replacement for in-person encounters for all urologic conditions, but rather another tool in our armamentarium," writes Adele M. Caruso, DNP, CRNP, FAANP.
April 26, 2021
Overall survival was similar between patients selecting primary intervention or active surveillance.
April 21, 2021
Frontline immune checkpoint inhibitor therapy may improve overall survival in this setting.